Meet Hopewell
Hopewell Therapeutics is discovering, synthesizing, and developing the next generation of tissue-targeted lipid nanoparticles (ttLNPs) to bring genomic medicines to patients. We’re pursuing opportunities to redefine the non-viral delivery space for novel genomic medicines by designing systemically administered LNPs to specifically target extrahepatic tissues and cells throughout the body. Hopewell has built a robust intellectual property portfolio with an expansive library of ionizable lipids and has established partnerships with several industry leading companies. We’re developing our own internal pipeline, initially targeting diseases of the lung, while concurrently exploring the potential of our ttLNP platform for patients with unmet needs in oncology, infectious diseases, rare genetic diseases and neurological disorders.
Our History
Our ttLNP platform was transformed by a decade of research and foundational intellectual property from Tufts University, where our Founder and Chief Technology Officer, Qiaobing Xu, Ph.D., is a professor of Biomedical Engineering. Hopewell holds exclusive licenses to the Tufts-derived ttLNP intellectual property estate for use in a broad field of clinical and commercial applications.
Founder
Scientific Advisors
ROBERT S. LANGER
Institute Professor, MIT
DAVID WALT
Professor, Harvard Medical School